ONC BeOne Medicines Ltd.
USHealthcareAs of 2026-10-08
Why ONC matters now
BeOne Medicines Ltd. (ONC) is a US stock in Healthcare. The latest InvestLog snapshot shows $350.08 with -3.83% on the session and $37.41B in market capitalization; recent performance reads 1-month -9.04% and YTD -11.08%.
The latest financial table shown here is Q1 2026, with revenue of $1.51B, net income of $227.4M, and EPS of $25.35. Investors can compare that operating picture with valuation signals such as P/E 113.15 and FCF yield 3.3%.
InvestLog's latest related AI research is a Insider Sale note titled "Wang Xiaodong sells $11.3M of ONC". The latest indexable market news headline is "Oncolytics Biotech (TSE:ONC) Share Price Crosses Below 200 Day Moving Average – Here’s Why" from Defense World.
Additional event context on this page matters because analyst consensus is Buy with a median target of $409.00; recent insider activity includes Wang Lai filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
113.15
PEG
0.78
P/B
9.73
P/S
5.84
EV/EBITDA
36.72
DCF Value
$-4,261.15
FCF Yield
3.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
87.2%
Operating Margin
12.0%
Net Margin
8.9%
ROE
12.1%
ROA
6.0%
ROIC
7.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.51B | $227.4M | $25.35 |
| Q4 2025 | $1.50B | $66.5M | $6.76 |
| FY 2025 | $5.34B | $286.9M | $32.11 |
| Q3 2025 | $1.41B | $124.8M | $13.52 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$399.11
Target (Median)
$409.00
Target Range
$340.00 - $436.00
Trading Activity
Insider Trades
Related AI Research
Wang Xiaodong sells $11.3M of ONCWang Xiaodong 内部减持 百济神州 (ONC) $11.3M
Wang Xiaodong (Director, Other, Chair, Scientific Advisory Brd) sold 31,028 shares of BeOne Medicines AG (ONC) on 2026-09-28, at an average price of $364.79, for approximately $11.3M.Wang Xiaodong（Director, Other, Chair, Scientific Advisory Brd）于 2026-09-28 卖出 BeOne Medicines AG（ONC）31,028 股，平均价格 $364.79，合计约 $11.3M。该交易于 2026-09-30 通过 SEC 原始 Form 4 披露。
Wang Xiaodong sells $13.4M of ONCWang Xiaodong 内部减持 百济神州 (ONC) $13.4M
Wang Xiaodong (Director, Other, Chair, Scientific Advisory Brd) sold 38,287 shares of BeOne Medicines AG (ONC) on 2026-09-08, at an average price of $349.10, for approximately $13.4M.Wang Xiaodong（Director, Other, Chair, Scientific Advisory Brd）于 2026-09-08 卖出 BeOne Medicines AG（ONC）38,287 股，平均价格 $349.10，合计约 $13.4M。该交易于 2026-09-10 通过 SEC 原始 Form 4 披露。
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Country
US
Exchange
—
Beta
0.49
BeOne Medicines Ltd. (ONC), initially founded in 2010 as BeiGene, stands as a prominent global oncology enterprise committed to identifying, advancing, and bringing to market cutting-edge cancer treatments. The company underwent a significant transformation, rebranding as BeOne in late 2024 and subsequently relocating its headquarters from Cambridge, Massachusetts, to Basel, Switzerland, in 2025. With a vast operational footprint extending across more than 45 countries and six continents, BeOne has firmly established itself as a leader in both immuno-oncology and targeted therapy solutions. Its strong product lineup includes key assets such as Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved worldwide for a variety of cancer types, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that has surpassed $1.3 billion in annual revenue and is approved in major regions like the U.S., Europe, and China. BeOne's strategic foundation combines proprietary research and development efforts with the integration of compounds obtained through external alliances, thereby fueling a comprehensive pipeline addressing both blood cancers and solid tumors.